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The purpose  of this study was to compare three hep- 
arin-binding plasma proteinase inhibitors in order to 
identify common  and unique features of heparin bind- 
ing and heparin-enhanced proteinase inhibition. Ex- 
periments with antithrombin, heparin cofactor, and 
protein C inhibitor were performed under identical 
conditions in order to facilitate comparisons. Synthetic 
peptides corresponding to the putative heparin binding 
regions of antithrombin, heparin cofactor, and protein 
C inhibitor bound to heparin directly and interfered in 
heparin-enhanced proteinase inhibition assays. All 
three inhibitors obeyed a ternary complex mechanism 
for heparin-enhanced thrombin inhibition, and the op- 
timum heparin concentration was related to the appar- 
ent heparin affinity of the inhibitor. The maximum 
inhibition rate and rate enhancement due to heparin 
appeared to be unique properties of each inhibitor. In 
assays with heparin oligosaccharides of known size, 
only the antithrombin-thrombin reaction exhibited a 
sharp threshold for rate enhancement at 14-16 sac- 
charide units. Acceleration of antithrombin inhibition 
of factor Xa, heparin cofactor inhibition of thrombin, 
and protein C inhibitor inhibition of thrombin, acti- 
vated protein C, and factor Xa  did not require a mini- 
mum saccharide size. The differences  in heparin size 
dependence and rate enhancement of proteinase inhi- 
bition by these inhibitors might reflect  differences  in 
the importance  of the ternary complex mechanism  and 
other mechanisms, alterations in inhibitor reactivity, 
and orientation effects in heparin-enhanced proteinase 
inhibition. 
Heparin is a glycosaminoglycan that has been widely used 
as an anticoagulant drug. It is a highly negatively charged 
molecule  composed of alternating glucosamine and iduronic 
acid residues that  are sulfated (1). Heparin  interacts with a 
number of plasma proteins including three plasma proteinase 
inhibitors:  antithrombin (historically known as  antithrombin 
111), heparin cofactor (also called heparin cofactor 11), and 
protein C inhibitor. These  proteins  are members of the serine 
proteinase  inhibitor family of proteins (serpins),’ of which al- 
proteinase inhibitor is the prototype (2). Heparin increases 
the rate of proteinase inhibition by the  three heparin-binding 
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inhibitors,  in some cases up to several thousand-fold (3). The 
therapeutic action of unfractionated heparin is believed to 
depend primarily on heparin-accelerated inhibition of throm- 
bin by antithrombin (4). The importance of antithrombin is 
documented by the incidence of thrombotic disease in patients 
with antithrombin deficiencies or abnormal antithrombin 
molecules (5). Similar clinical correlations are weak  for hep- 
arin cofactor (6) and non-existent for protein C inhibitor; 
thus it is difficult to assign discrete physiological roles for 
these two inhibitors. 
The fact that heparin  enhances proteinase inhibition by all 
three heparin-binding serpins suggests that a common mech- 
anism is involved.  However, the heparin-antithrombin  inter- 
action has been extensively studied, and  the heparin-heparin 
cofactor and  the heparin-protein C inhibitor  interactions less 
so, and it is clear that differences among these serpins do 
exist. Because of the difficulty in directly comparing results 
from a number of sources, the present study was undertaken. 
This report  attempts to distinguish general rules for heparin 
stimulation of proteinase inhibition from the unique re- 
sponses of each serpin. The experiments described below 
examine the heparin binding properties and proteinase inhi- 
bition reactions in the presence of heparin under identical 
conditions in order to facilitate comparisons. Some of the 
data appeared previously in abstract form (7). The preceding 
paper describes some heparin binding properties of protein C 
inhibitor (8). 
EXPERIMENTAL  PROCEDURES 
Materials-All serpins  and proteinases were purified from human 
plasma (8). All other reagents were identical to those in the preceding 
report (8). Heparin oligosaccharides (6-20 saccharide units) were the 
gift of Dr. Michel Canton, American Bioproducts. 
Peptide Synthesis-Peptides were synthesized as described (8) 
according to  the reported sequences of the inhibitors (2). Fidelity of 
synthetic peptides was confirmed either by amino acid sequence or 
composition analysis. Heparin affinity of peptides was measured by 
passing the peptide through a  1-ml column of heparin-agarose in 20 
mM HEPES, 0.1% PEG 8000, pH 7.4, and eluting with a linear salt 
gradient. 
Peptide Competition Assays-Peptides (0.1-100 p ~ )  in 20 mM 
HEPES, 150 mM NaCl, 0.1% PEG, pH 7.4, were added to assay 
mixtures containing 2 mg/ml bovine serum albumin, 0.05-0.15 pg/ml 
heparin (for antithrombin and heparin cofactor assays) or 1 pg/ml 
heparin (for protein C  inhibitor  assays), and 50 nM inhibitor in the 
same buffer at 25 “C. Reactions were started with the addition of 5 
nM thrombin or activated protein C. After incubation, remaining 
proteinase activity was measured using 0.15 mM chromogenic sub- 
strate with 2 mg/ml Polybrene. Substrate hydrolysis was linearly 
related to proteinase concentration. Exceptions to  the above proce- 
dure were: 500 nM antithrombin was used with 50 nM factor Xa; 100 
nM protein C  inhibitor was used with 10 nM activated protein C, and 
1 pg/ml dermatan sulfate was used in some heparin cofactor assays. 
Control experiments performed in the absence of heparin or in the 
absence of inhibitor verified that peptides had no direct effect on 
proteinase or inhibitor activity. 
Effect of Heparin on Thrombin Inhibition-Assays contained 10 
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nM antithrombin, protein C  inhibitor,  or heparin cofactor, 2 mg/ml 
bovine serum albumin, and 0.01-1000 pg/ml heparin in 20 mM 
HEPES, 150 mM NaCl, 0.1% PEG,  pH 7.4 at 25  "C. Reactions were 
started with the addition of 1 nM thrombin. Following incubation, 
thrombin activity was determined by hydrolysis of chromogenic sub- 
strate containing 2 mg/ml Polybrene. Second order inhibition rate 
constants were calculated as -In a/t [A where a is the fractional 
proteinase activity remaining relative to  the uninhibited  control,  t is 
the time of incubation, and [A is the inhibitor concentration. For 
assays comparing a-thrombin and 7,-thrombin, the conditions were 
5 nM antithrombin, 5 nM protein C  inhibitor, 20 nM heparin cofactor, 
and 0.5 nM thrombin. 
Heparin affinity chromatography of antithrombin, heparin cofac- 
tor, and protein C  inhibitor was performed using a  Pharmacia  LKB 
Biotechnology Inc. fast  protein liquid chromatography system and a 
5-ml column of heparin-Sepharose in 20 mM HEPES, 10 mM NaC1, 
0.1% PEG, pH 7.4. Samples were eluted with a 1 ml/min linear  salt 
gradient from 10 mM to 1.2 M NaCl. Proteins were detected by 
absorbance at 280 nM. Salt concentration corresponding to peak 
elution was the average of six to nine runs. 
Effect of Saccharide Chain Length-Assays contained 62.5 nM 
antithrombin, protein C inhibitor, or heparin cofactor, 2 mg/ml 
bovine serum albumin, and 500 mM heparin oligosaccharide (0.9 pg/ 
ml for the hexamer and 3.0 pg/ml for the 20-mer). Reactions were 
started with the addition of 5 nM thrombin, activated protein C, or 
factor Xa. After incubation, proteinase activity was determined by 
hydrolysis of the appropriate chromogenic substrate. Inhibition rate 
constants were calculated as described above. The results were nor- 
malized by setting the inhibition rate  in the absence of heparin to 1.0 
and the inhibition rate obtained with the 20-mer to 2.0. 
Computer-aided Molecular  Modeling-The three-dimensional 
structure of al-proteinase  inhibitor (9) was obtained from the Protein 
Data Bank. The amino acid sequences of antithrombin, heparin 
cofactor, and protein C  inhibitor were obtained from the literature 
(2) and modeled by mutating the corresponding residues in al- 
proteinase  inhibitor using the molecular modeling software SYBYL 
(Tripos Associates, St. Louis, MO). The amino termini, insertions, 
and deletions that had no counterparts in al-proteinase inhibitor 
were not modeled. The energy of each mutated protein was minimized 
using the programs SYBYL or AMBER.' 
RESULTS 
Models of Heparin-binding Sites-Peptides corresponding 
to  the putative heparin-binding sites of antithrombin, heparin 
cofactor, and  protein  C  inhibitor were synthesized, and  their 
identity  as heparin-binding peptides was confirmed by their 
ability to bind heparin directly and indirectly in proteinase 
inhibition assays. Table I lists the apparent affinity of the 
three  serpins  and  synthetic peptides for immobilized heparin. 
The peptides corresponding to  the putative heparin binding 
region of antithrombin (AT 124-140) bound with lower affin- 
ity than native antithrombin, possibly because the peptide 
did  not assume the same conformation as  the corresponding 
structure in the native molecule, or because additional  struc- 
tural elements were required. The peptides corresponding to 
the putative heparin binding regions of heparin cofactor (HC 
183-200) and protein C  inhibitor (PC1 264-283) bound with 
greater affinity than  the native molecules, indicating that  the 
heparin-binding sites in the native molecules might be 
masked. In two cases, peptides containing the same residues 
as the putative heparin binding region but in random se- 
quence, bound with lower affinity (AT 124-140 random and 
PC1 264-283 random), suggesting that  the exact sequence of 
the peptide, and thus  its structure, was  more important than 
charge alone for binding to heparin. 
The peptides were also tested for their ability to compete 
with serpins for heparin binding in proteinase inhibition 
assays. Increasing concentrations of peptides were added to 
Software, version 3.1, obtained from U. C. Sing, P. K. Weiner, J. 
W. Caldwell, and P. A. Kollman, P.A., Dept. of Pharmaceutical 
Chemistry, University of California, San Francisco. 
mixtures of serpin, proteinase, and heparin such that com- 
petition between peptide and inhibitor for heparin would 
decrease the efficiency of proteinase inhibition. Table I1 pre- 
sents  the results of these experiments, expressed as  the con- 
centration of peptide required to block half the proteinase 
inhibition activity of the serpin. Peptides corresponding to 
the putative heparin-binding sites of the three  serpins com- 
peted with the parent serpin in  proteinase inhibition assays. 
Furthermore, heparin cofactor-derived peptides and protein 
C inhibitor-derived peptides competed with antithrombin, 
and  antithrombin-derived peptides competed with protein  C 
inhibitor. The peptide corresponding to the heparin-binding 
site  in  antithrombin competed with antithrombin  in assays 
for thrombin or factor Xa inhibition, and peptides from 
protein C inhibitor competed with protein C inhibitor in 
assays for thrombin or activated protein C inhibition. The 
ability of the various peptides to compete for heparin binding 
regardless of the particular serpin or proteinase involved 
indicates a general ability to bind heparin, and rules out 
specific effects of the peptides on these  inhibitors  or  protein- 
ases. 
Dermatan sulfate, in addition to heparin, accelerates 
thrombin inhibition by heparin cofactor, but  not  antithrom- 
bin or protein C inhibitor (8, 10). Two peptides from the 
putative glycosaminoglycan binding region of heparin cofactor 
(HC 173-190 and HC 183-200) competed for heparin binding, 
with HC 183-200 being more effective. However, both pep- 
tides were equally effective in dermatan sulfate-containing 
thrombin inhibition assays. These results suggest that the 
structural  determinants for heparin or  dermatan sulfate bind- 
ing to heparin cofactor differ somewhat. As a positive control, 
the known heparin-binding  site of platelet factor 4 (PF4 74- 
85, Ref. 11) was synthesized and tested for its ability to 
compete for heparin binding in proteinase inhibition assays. 
The platelet factor 4-derived peptide competed in all cases 
except when dermatan  sulfate was used, which might reflect 
the ability of platelet factor 4 to bind heparin but  not der- 
matan sulfate. In most cases, the peptides with random se- 
quences were less effective at competing for heparin binding 
than their native sequence counterparts (antithrombin-de- 
rived peptides in  antithrombin assays and protein C  inhibitor- 
derived peptides in protein C  inhibitor assays). In only one 
case (antithrombin-derived peptides in  the protein C inhibi- 
tor-thrombin assay) was the random peptide more effective 
than the native peptide. On the whole, the results suggest 
that  the specific sequence of the peptide, not merely its charge, 
is important for heparin binding. The peptide with the great- 
est  apparent affinity for immobilized heparin, PC1 264-283, 
was also one of the most effective at competing for heparin 
binding in proteinase inhibition assays. The ability of the 
serpin-derived peptides to bind heparin, as measured by two 
different methods, provides proof that these are models of the 
heparin-binding sites in the parent inhibitors. 
Effect of Heparin on Thrombin Inhibition-The accelerat- 
ing effect of heparin on thrombin inhibition by antithrombin, 
heparin cofactor, and  protein  C  inhibitor  is well-documented. 
In  this study, reactions with each serpin were compared under 
identical conditions of buffer, temperature, heparin prepara- 
tion,  and proteinase, so that  the only variable was the inhib- 
itor. Constant protein concentrations were used since they 
can affect the results (12). Fig. 1 shows the effect of heparin 
concentration on the rate of thrombin inhibition by each of 
the serpins. The shapes of these curves are  consistent with 
the ternary complex model of heparin action (13), in which 
lower concentrations of heparin bind both proteinase and 
inhibitor, thereby bringing them  into closer proximity for a 
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TABLE I 
Heparin  affinity of proteins  and  synthetic  peptides 
Protein/ueutide  Sequence  Heparin  affinity” 
Antithrombin 
AT 124-140 random 
Protein  C  inhibitor 
























240 ~~~ ~ ~~ 
a Heparin affinity is given as  the salt  concentration required for elution from a  1-ml column of heparin-agarose. 
This value is an indication of heparin affinity, but is not identical to  an affinity constant, which requires more 
rigorous measurement. 
Numbers refer to  the amino acid sequence of the  parent protein,  antithrombin. 
Numbers refer to  the amino acid sequence of the  parent protein, protein C inhibitor. 
Numbers refer to  the amino acid sequence of the  parent protein, heparin cofactor. 
e Numbers refer to  the amino acid sequence of the parent  protein,  platelet factor 4. 
TABLE I1 
Competition  between  serpins  and  synthetic  peptides  for 
heparin binding 
Assay“ Peptide half-maximal 
Conc. for 
effectb 
P M  
Antithrombin-thrombin AT 124-140 12 
AT 124-140 random 18 
PC1 264-283 random 3.5 
PC1 264-283 0.4 
HC 173-190 35 
HC 183-200 1.2 
PF4 74-85 38 
Antithrombin-factor  Xa AT 124-140 24 
Protein  C  inhibitor-throm- AT 124-140 15 
bin AT 124-140 random 3.3 
PC1 264-283 0.9‘ 
PC1 264-283 random 12‘ 
PF4 74-85 70 
Protein  C  inhibitor-pro- PC1 264-283 1.5‘ 
tein  C PC1 264-283 random 13‘ 
Heparin cofactor-thrombin HC 173-190 3.7 
HC 183-200 0.5 
PF4 74-85 48 
Heparin cofactor-throm- HC 173-190 3.5 
bind HC 183-200 3.1 
P F ~  74-85 >loo 
a Assays contained the indicated inhibitor and proteinase as well 
as heparin, as described under “Experimental Procedures.” 
The peptide concentration that blocked 50% of inhibition activity 
was measured using inhibition activity in the absence of peptide as 
the starting (0%) point and proteinase activity in the absence of 
inhibitor as  the end (100%) point. Plots of proteinase activity uersus 
peptide concentration were typically sigmoidal. 
Results were taken from Ref. 8. 
Assay contained dermatan  sulfate rather  than heparin. 
faster  rate of reaction. Higher concentrations of heparin act 
to sequester the reactants, restoring the reaction rate to 
normal. The optimum heparin concentration, which is the 
concentration corresponding to maximum inhibition  rate, is 
expected to be a function of the affinity of the inhibitor for 
heparin, since all  other variables were constant. This was in 
fact the case, as shown in Table 111: the optimum heparin 
concentration was inversely related to  apparent heparin affin- 
ity for each ~ e r p i n . ~  
Unfractionated heparin and a fraction of heparin with high affin- 
ity for antithrombin produced the same degree of inhibition rate 
0.01 0.1 1 10 1w 1000 
Heparin (kg/rnl) 
FIG. 1. The effect of heparin on thrombin inhibition rate. 
The rate of thrombin inhibition by antithrombin (m), protein C 
inhibitor (A), and heparin cofactor (0) was measured as a function 
of heparin concentration, as described under “Experimental Proce- 
dures.” The inhibition rates were normalized to give a maximum rate 
of 1.0. The actual values for maximum inhibition rates  are given in 
Table 111. 
If the  ternary complex mechanism were the only one in- 
volved in heparin-enhanced thrombin inhibition, then the 
degree of rate  enhancement would  be expected to be similar 
for all serpins. Table I11 shows that  this is not the case, as 
there was no obvious relationship between heparin affinity 
and maximum thrombin inhibition rate or degree of rate 
enhancement. For example, heparin cofactor, which had the 
lowest heparin affinity, exhibited the greatest increase in 
thrombin inhibition rate, approximately 9000-fold. 
Other  studies (14, 15) have proposed that heparin, in addi- 
tion to serving as a template for the inhibitor-proteinase 
reaction, causes the exposure of a secondary binding site for 
thrombin  in heparin cofactor. yT-Thrombin, which lacks the 
structure necessary for binding to  this site, is unable to react 
with heparin cofactor as rapidly as  a-thrombin in the presence 
of heparin (16). Table IV lists the rate  constants for inhibition 
enhancement and  the same heparin optimum in an antithrombin- 
thrombin assay system, although the high affinity heparin showed 
greater rate  enhancement at lower concentrations, relative to unfrac- 
tionated heparin. In  an antithrombin-factor  Xa assay system, heparin 
with high affinity for antithrombin produced maximal rate enhance- 
ment at a lower concentration than  the unfractionated heparin, but 
the maximum inhibition rate was the same (results  not shown). Thus, 
fractionation of heparin by affinity for antithrombin does not influ- 
ence the parameters examined here, namely optimum heparin con- 
centration  and maximum thrombin inhibition rate. 
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TABLE 111 
Properties of thrombin-serpin reactions 





mM NaCl pg/ml "' 
Antithrombin 925  2.5 10.2 2500 
Protein C inhibitor 505 6 0.16 15 
Heparin cofactor 365  200 4.6 9000 
Heparin affinity is given as  the salt  concentration required for 
peak elution from heparin-Sepharose using a fast protein liquid 
chromatography system. The  apparent heparin affinities given here 
are higher than those in Table I. The differences are most likely due 
to  the higher heparin content of the heparin-Sepharose compared to 
heparin-agarose produced in the laboratory. 
The optimum heparin is the concentration at  which the maximum 
inhibition rate occurs, as shown in Fig. 1. 
The rate increase is calculated as  the ratio of the maximum rate 
to  the rate  in the absence of heparin. 
TABLE IV 
Muximum rates of inhibition of a-thrombin and 7,-thrombin by 
three inhibitors in the presence of heparin 
The second-order inhibition rate  constants  are given in units of 
IO+ M" rnin". 
Semin  a-Thrombi   rr-Thro bin Ratio" 
Antithrombinb 115 46.6 2.5 
Protein C inhibitor 1.31 .167 7.8 
Heparin cofactorb 30.0 ,017 1760 
The ratio is calculated as  the  rate constant for a-thrombin inhi- 
Rate  constants were taken from Ref.  16. 
bition divided by the rate constant for 7,-thrombin inhibition. 
of a-thrombin  and 7,-thrombin by the  three heparin-binding 
serpins in the presence of optimal concentrations of heparin. 
For  a given serpin, the optimum heparin concentration was 
the same for a-thrombin and yT-thrombin. Only heparin 
cofactor exhibited a  dramatic difference in heparin-catalyzed 
inhibition rate for the two forms of thrombin (1760-fold 
difference), while antithrombin  and  protein C inhibitor ex- 
hibited modest differences (2.5-fold for antithrombin  and 7.8- 
fold for protein C inhibitor). Thus, heparin cofactor appears 
to  be unique among the  three serpins by virtue of its secondary 
binding mechanism. 
Effect of Heparin Saccharide Chain Length-The influence 
of heparin saccharide chain length on the  rate of proteinase 
inhibition by the three heparin-binding serpins was examined 
in order to determine the importance of the ternary complex 
mechanism for proteinase inhibition, which involves simul- 
taneous binding of the inhibitor  and proteinase to heparin. If 
the ternary complex mechanism were the only one involved, 
then small heparin oligosaccharides would not accelerate 
thrombin inhibition until a minimum heparin saccharide 
chain length, capable of binding both  serpin  and proteinase, 
were reached. If other mechanisms were involved, such as 
changes in reactivity of the serpin  or secondary binding sites 
as described above for heparin cofactor, then  the saccharide 
size dependence of the inhibition reaction might not exhibit 
a threshold phenomenon. Some previous studies have re- 
ported a variety of minimum saccharide chain lengths re- 
quired to accelerate antithrombin (17) and heparin cofactor 
(18, 19) reactions. The present study examined the three 
heparin-binding serpins under identical conditions'using hep- 
arin oligosaccharides of known chain length, from 6 to 20 
saccharide units. (Saccharides of this length would not be 
capable of binding more than two protein molecules;  Ref. 20.) 
Because the same concentration of heparin accelerates throm- 
bin inhibition to various degrees depending on the serpin  (as 
shown in Fig. l), the results were normalized by setting the 
inhibition rate in the absence of heparin to 1.0 and the 
inhibition rate obtained with the 20-mer to 2.0. The results 
are shown in Fig. 2. Only the antithrombin-thrombin reaction 
showed a  sharp  threshold with increasing size of the heparin 
oligosaccharide: inhibition activity increased at 16 saccharide 
units. The antithrombin-factor  Xa reaction exhibited an al- 
most linear relationship between inhibition rate  and saccha- 
ride chain length. The effect of heparin chain length on the 
heparin cofactor-thrombin and  protein C inhibitor-thrombin 
reactions was intermediate to  that of the two antithrombin 
reactions. The heparin saccharide chain length dependence 
for the protein C inhibitor-activated  protein C and protein C 
inhibitor-factor  Xa reactions was almost identical to  that of 
the protein C inhibitor-thrombin reaction. One interpretation 
of these results is that  the template mechanism is clearly 
important for the antithrombin-thrombin reaction, but less 
so for the heparin cofactor and protein C inhibitor reactions, 
and possibly not at all for the antithrombin-factor Xa reac- 
tion. 
DISCUSSION 
In order to distinguish general features of heparin-binding 
serpins from features unique to each inhibitor, the three 
proteins were studied in parallel. The putative  heparin-bind- 
ing sites in antithrombin, heparin cofactor, and protein C 
inhibitor have been identified on the basis of the following: 
1) high charge density; 2) results of chemical modification of 
residues that affect heparin interactions in antithrombin (21, 
22) and heparin cofactor (23); 3) natural  mutations that affect 
heparin binding in  antithrombin  (21,24)  and heparin cofactor 
(25); 4) site-directed mutagenesis in heparin cofactor (26), 
and  5) heparin binding activity of synthetic peptides (8). The 
heparin binding regions in antithrombin  and heparin cofactor 
are located primarily in the D helix, and in fact, these  proteins 







8  12  16 20 
Number of saccharide units 
FIG. 2. The effect of heparin saccharide chain length on 
proteinase inhibition. The  rate of proteinase inhibition by three 
serpins as a function of heparin saccharide chain length was measured 
as described under "Experimental Procedures." Antithrombin-throm- 
bin (H), protein C inhibitor-thrombin (+), heparin cofactor-thrombin 
(O), and antithrombin-factor Xa (0). Inset, protein C inhibitor- 
activated protein C (.) and protein C inhibitor-factor Xa (0). The 
results were normalized to give a range of rates from 1.0 to 2.0. The 
actual  rate constants span the following values (from 6 to 20 saccha- 
ride units):  antithrombin-thrombin: 0.04-7.74 X 10' M" min"; hep- 
arin cofactor-thrombin: 0.04-5.62 X lo6 M" rnin"; protein C inhibi- 
tor-thrombin: 1.01-1.80 X lo6 M" rnin"; antithormbin-factor Xa: 
0.25-4.40 X lo7 M" rnin"; protein C inhibitor-activated protein c: 
0.92-3.94 X lo6 M" min"; protein C inhibitor-factor Xa: 1.78-2.64 X 
lo6 M" rnin". 
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in antithrombin  and 165-195 in heparin cofactor). Protein C 
inhibitor is not homologous to either  antithrombin or heparin 
cofactor in this region, and  the putative  heparin-binding  site 
in protein C inhibitor is assigned to  the H helix (residues 
264-273, Refs. 8, 27).The homology among serpins (2) and 
the similarity of crystal  structures of other  serpins (28, 29) 
allow the heparin-binding serpins to be  modeled with confi- 
dence. The peptide backbone structures of antithrombin, hep- 
arin cofactor, and protein C inhibitor are shown in Fig. 3. 
Arginine and lysine residues in  the primary heparin-binding 
sites in the  three serpins  are shown with van der Waals radii 
highlighted, Not shown are  additional residues that are  in- 
volved in heparin binding, such as the amino termini of 
antithrombin  and  protein C inhibitor, which have been pro- 
posed to participate in heparin binding on the basis of other 
molecular modeling studies (2, 27). In  any case, the primary 
heparin-binding sites in the three serpins are assigned to 
surface residues that form a-helices  in the proteins, and  the 
location of the helix is  the same in antithrombin  and heparin 
cofactor, but  not protein C inhibitor. 
The ability of synthetic peptides from antithrombin, hep- 
arin cofactor, and  protein C inhibitor to bind heparin (and 
dermatan sulfate, in the case of heparin cofactor-derived 
Antithrombin 
Heparin  Cofactor 
Protein C Inhibitor 
FIG. 3. Molecular  models of heparin-binding serpins. Com- 
puter-generated molecular models of antithrombin, heparin cofactor, 
and protein C inhibitor were constructed by altering the three- 
dimensional structure of a,-proteinase inhibitor. Lysine and arginine 
residues of the putative heparin-binding sites  in  antithrombin (K107, 
K114, K125, R129, R132  K133, K136), heparin cofactor (K165, K173, 
R184, K185,  R189,  R192, R193). and protein C inhibitor (K266, R269, 
K270, K273, K276, K277, R278) are shown with van der Waals radii 
highlighted. Because the models depict reactive site-cleaved serpins, 
the residues of the reactive site are at opposite sides of the molecule. 
peptides) provides additional proof that these sequences cor- 
respond to  the heparin-binding sites in the  three serpins. This 
is the first  demonstration that heparin-binding peptides de- 
rived from different serpins  are functionally similar. 
The effect of heparin on the inhibition of thrombin by 
antithrombin, heparin cofactor, and protein C inhibitor also 
shows that the three inhibitors are similar in obeying the 
ternary complex mechanism. According to  this theory (13) 
both  inhibitor and proteinase bind to heparin so that colocal- 
ization of reactants increases the reaction rate. The rate 
reaches a maximum and  then decreases as  the heparin con- 
centration increases. The optimum heparin concentration 
appears to be related to  the  apparent heparin affinity of the 
serpin. In these experiments, thrombin was used, but the 
preceding paper reports that  the affinity of the proteinase 
also influences the optimum heparin concentration (8). Other 
mechanisms must also govern the effect of heparin on serpin 
reactivity, since the maximum inhibition rate and rate en- 
hancement varied among the serpins. 
The size of the heparin oligosaccharide capable of acceler- 
ating  thrombin  inhibition by the three  serpins provides infor- 
mation about possible mechanisms of heparin action. The 
sharp threshold in saccharide size dependence in the anti- 
thrombin-thrombin reaction is consistent with a mechanism 
in which both  inhibitor  and proteinase bind heparin; ternary 
complex formation appears to be less important for protein C 
inhibitor or heparin cofactor inhibition reactions, at least 
with the small saccharides tested in this study. No conclusions 
can be drawn regarding the size of the heparin-binding sites 
in protein C inhibitor or heparin cofactor, since these serpins 
did not  exhibit  a threshold phenomenon. Because thrombin 
binds approximately 6 saccharide residues (30),  antithrombin 
must accommodate 8-10 saccharide units in its heparin- 
binding site (14-16 minus 6). 
We propose that while antithrombin, heparin cofactor, and 
protein C inhibitor  share some features of heparin-enhanced 
proteinase inhibition, the molecular events that determine 
maximum inhibition rate,  rate  enhancement,  and heparin size 
dependence are unique to each inhibitor. Possible mechanisms 
for heparin action are discussed below for each serpin, consid- 
ering the findings of this study and  other work. Three factors 
are  taken  into account: ternary complex or template effects, 
changes in reactivity of the serpin, and orientation of the 
serpin relative to  the proteinase. 
Antithrombin differs dramatically in inhibition of thrombin 
and factor Xa. The heparin size dependence data suggest that 
a  template mechanism is important in thrombin inhibition. 
These  data  are also consistent with the possibility that bind- 
ing of 14-16 saccharide units is required to elicit a change in 
antithrombin reactivity. This mechanism seems unlikely 
since the heparin dependence of thrombin inhibition shows 
the bell-shaped curve characteristic of a  ternary complex (13, 
31). Furthermore, the antithrombin-factor  Xa reaction mech- 
anism, in  which the ternary complex mechanism is not im- 
portant  (32), showed no threshold at 14-16 residues. Other 
studies have concluded that a heparin-induced conforma- 
tional change in  antithrombin is not  important in thrombin 
inhibition (33-35). We propose that during thrombin inhibi- 
tion by antithrombin, heparin acts  as  a  template to increase 
the  rate of reaction of inhibitor  and proteinase. In addition, 
the orientation of the reactants when they are bound to 
heparin may be optimized so that a 2500-fold increase in 
reaction rate is possible, and  this probably masks the more 
limited effect of a heparin-induced increase in antithrombin 
reactivity. The optimal orientation of inhibitor  and proteinase 
might be such that  the reactive site of antithrombin would  be 
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directly apposed to the active site of thrombin when the 
molecules, still bound to heparin, collide. This scenario is 
consistent with a finely evolved system for limiting thrombin 
activity in vivo, which is believed to be the primary role  of 
antithrombin (3). 
Antithrombin inhibition of factor Xa, in contrast, depends 
almost entirely on the heparin-induced increase in reactivity 
of antithrombin (36). This is consistent with the lack of a 
heparin oligosaccharide  size threshold  the larger the saccha- 
ride, the greater the probability that  it contains the pentasac- 
charide sequence that binds with high affinity to antithrombin 
(37). The binding of this sequence elicits a conformational 
change in antithrombin, detected by fluorescence changes, 
that is correlated with its increased reactivity (36). The role 
of heparin as  a  template  in the antithrombin-factor  Xa reac- 
tion is minimal (32). Although the affinity of factor Xa for 
immobilized heparin is significant (eluting at 445 mM NaC1, 
Ref. 8) and  a  ternary complex might be expected to form, the 
orientation of the enzyme and  inhibitor may not favor inter- 
action.  This might also be responsible for the limited heparin- 
induced rate  enhancement for factor Xa compared to throm- 
bin inhibition (31). The relative contributions of ternary 
complex formation and increased antithrombin reactivity ap- 
pear to differ among antithrombin-proteinase pairs. For ex- 
ample, the increase in kallikrein inhibition is modest (about 
&fold) and does not follow a template mechanism (results 
not shown), while inhibition of factor IXa is accelerated 
significantly by heparin and  a  ternary complex mechanism 
seems to be involved (31). The differences might be deter- 
mined by the orientation of the particular proteinase when it 
is bound to heparin. Other  reports suggest that  the orientation 
effect might include neutralization of positive charges on the 
inhibitor by heparin, which could contribute to more favorable 
interactions with cationic proteinases (38). 
Thrombin inhibition by heparin cofactor follows the tem- 
plate mechanism as shown in  the present study and other 
reports (39). The shape of the heparin size dependence curve 
initially suggests that a heparin-induced change in heparin 
cofactor reactivity also occurs.  However, the evidence is con- 
sistent with a secondary thrombin-binding site in heparin 
cofactor, consisting of acidic residues near the amino terminus 
that are made  accessible when a glycosaminoglycan binds to 
heparin cofactor (14, 15). This secondary binding mechanism 
is illustrated by the failure of heparin to accelerate inhibition 
of yT-thrombin, which lacks the structure required to bind 
this acidic  region of heparin cofactor (16). Since no minimum 
saccharide size  was required for heparin acceleration of 
thrombin inhibition by heparin cofactor, even small saccha- 
rides must be able to expose the acidic region (by displacing 
it from the heparin binding region of heparin cofactor, Refs. 
14, 15). This is consistent with a report that small dermatan 
sulfate saccharides are capable of increasing heparin cofactor 
reactivity without supporting a template mechanism (40). 
Studies that have found a minimum size requirement of 18- 
26 heparin saccharide units in heparin cofactor reactions (18, 
19) might have used different heparin fractionation tech- 
niques or different approaches to assigning threshold  inhibi- 
tion  rate values. The combination of the secondary binding 
site mechanism, which might also orient  inhibitor  and  pro- 
teinase,  and the ternary complex mechanism is able to accel- 
erate thrombin inhibition 9000-fold, even though the reactive 
site sequence of heparin cofactor is Leu-Ser, which is not 
expected to be a good substrate for thrombin (41). It is also 
possible that  the geometry of the ternary complex formed 
with heparin differs from that formed with dermatan sulfate. 
Although dermatan sulfate has lower affinity than heparin 
for heparin cofactor, it enhances thrombin inhibition to a 
greater extent (42). 
The results of the present  study  and those of the preceding 
report (8) indicate that protein C  inhibitor obeys the template 
mechanism for heparin-enhanced proteinase inhibition. How- 
ever, the absence of a  sharp  threshold for heparin oligosac- 
charide size dependence suggests that small saccharides might 
also directly alter  protein  C  inhibitor eactivity, as is the case 
for the antithrombin-factor Xa reaction. The poor proteinase 
inhibition rate  enhancement elicited by heparin (relative to 
antithrombin  or heparin cofactor inhibition rates) might re- 
flect less favorable orientation of inhibitor and proteinase 
when they  are bound to heparin. Thus, when heparin-bound 
inhibitor and proteinase collide, additional steps, such as 
dissociation from the heparin template, might occur  before a 
productive reaction could occur. This is particularly intriguing 
since the putative heparin-binding site of protein C inhibitor 
(the H helix) is in a location different from the heparin- 
binding sites in antithrombin or heparin cofactor (the D helix, 
Fig. 3). It is possible that the expected template effect of 
heparin is dampened by geometrical factors that hinder the 
approach of inhibitor  and proteinase. This is one explanation 
for the low maximum thrombin inhibition rate by protein C 
inhibitor, whose reactive site sequence, as in antithrombin, is 
Arg-Ser, a likely target for thrombin (43). Steric hindrance or 
other geometrical factors also might explain why inhibition 
of different proteinases is accelerated to various degrees by a 
given concentration of heparin (8). 
Full confirmation of the proposed mechanisms for heparin 
acceleration of proteinase inhibition by the  three heparin- 
binding serpins will require additional study, including an 
assessment of the contribution of geometric effects. In con- 
clusion, the ternary complex mechanism for heparin-en- 
hanced thrombin inhibition and the characteristics of the 
heparin-binding sites of antithrombin, heparin cofactor, and 
protein C inhibitor are common features of these serpins. 
However, the location of the heparin-binding site and the 
importance of the ternary complex mechanism and other 
mechanisms for heparin-enhanced proteinase inhibition are 
unique features of these serpins. It remains to be seen how 
closely the lesser-studied heparin-binding proteinase inhibi- 
tors, such as C1 inhibitor (44) and protease nexin I (45), 
follow the rules described above. A recent report on protease 
nexin I suggests that  its heparin-binding site resembles that 
in  antithrombin,  and heparin-enhanced proteinase inhibition 
obeys a  ternary complex mechanism (46). 
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